The potential role of next-generation sequencing in identifying <i>MET</i> amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance.

ABSTRACT:

Purposes

Osimertinib, one of the third-generation EGFR-tyrosine kinase inhibitors (TKIs) designed to target EGFR T790M mutation, significantly improves the prognosis of lung cancer. However, drug resistance still happens and MET amplification is responsible for one of the main causes. Fluorescence in situ hybridization (FISH) is the gold standard for MET amplification detection, but fundamentally limited by observer subjectivity. Herein, we assessed the value of next-generation sequencing (NGS) method in MET amplification detection in non-small cell lung cancer (NSCLC), as well as revealed the mutation profiling of NSCLC patients with osimertinib resistance to provide some valuable clues to the mechanisms of resistance.

Methods

A tot

SUBMITTER: Xiao X 

PROVIDER: S-EPMC11532092 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature